PE20150995A1 - Nuevos derivados de piridina - Google Patents

Nuevos derivados de piridina

Info

Publication number
PE20150995A1
PE20150995A1 PE2015000231A PE2015000231A PE20150995A1 PE 20150995 A1 PE20150995 A1 PE 20150995A1 PE 2015000231 A PE2015000231 A PE 2015000231A PE 2015000231 A PE2015000231 A PE 2015000231A PE 20150995 A1 PE20150995 A1 PE 20150995A1
Authority
PE
Peru
Prior art keywords
chloro
pyridine derivatives
new pyridine
cyclopropanecarbonyl
pyridin
Prior art date
Application number
PE2015000231A
Other languages
English (en)
Spanish (es)
Inventor
Lilli Anselm
David Banner
Wolfgang Haap
Bernd Kuhn
Thomas Luebbers
Jens-Uwe Peters
Beat Spinnler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20150995(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20150995A1 publication Critical patent/PE20150995A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PE2015000231A 2012-08-21 2013-08-19 Nuevos derivados de piridina PE20150995A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12181247 2012-08-21

Publications (1)

Publication Number Publication Date
PE20150995A1 true PE20150995A1 (es) 2015-06-29

Family

ID=46851300

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000231A PE20150995A1 (es) 2012-08-21 2013-08-19 Nuevos derivados de piridina

Country Status (24)

Country Link
US (1) US9409882B2 (Direct)
EP (1) EP2888244A1 (Direct)
JP (1) JP2015530997A (Direct)
KR (1) KR20150044947A (Direct)
CN (1) CN104583198A (Direct)
AR (1) AR092172A1 (Direct)
AU (1) AU2013305102A1 (Direct)
BR (1) BR112015003217A2 (Direct)
CA (1) CA2879796A1 (Direct)
CL (1) CL2015000354A1 (Direct)
CO (1) CO7200259A2 (Direct)
CR (1) CR20150073A (Direct)
EA (1) EA025166B1 (Direct)
HK (1) HK1206716A1 (Direct)
IL (1) IL237128A0 (Direct)
IN (1) IN2015DN00962A (Direct)
MA (1) MA37893A1 (Direct)
MX (1) MX2015002026A (Direct)
PE (1) PE20150995A1 (Direct)
PH (1) PH12015500262A1 (Direct)
SG (1) SG11201500900YA (Direct)
TW (1) TW201412728A (Direct)
WO (1) WO2014029722A1 (Direct)
ZA (1) ZA201500625B (Direct)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108699044B (zh) * 2016-02-26 2022-03-04 豪夫迈·罗氏有限公司 新吡咯烷衍生物
PL3575284T3 (pl) 2017-01-24 2021-12-27 Astellas Pharma Inc. Związek prolinamidu podstawiony fenylodifluorometylem
TW202607003A (zh) * 2024-08-05 2026-02-16 大陸商百放英庫醫藥科技(北京)有限公司 組織蛋白酶l抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903610D0 (sv) 1999-10-06 1999-10-06 Astra Ab Novel compounds II
WO2006073361A1 (en) 2005-01-06 2006-07-13 Astrazeneca Ab Novel pyridine compounds
KR20080092385A (ko) 2006-01-24 2008-10-15 액테리온 파마슈티칼 리미티드 신규한 피리딘 유도체
WO2008141119A2 (en) * 2007-05-09 2008-11-20 Vertex Pharmaceuticals Incorporated Modulators of cftr
BRPI0820203A2 (pt) 2007-11-30 2015-06-16 Hoffmann La Roche Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades
EP2262799B1 (en) 2008-03-06 2012-07-04 Actelion Pharmaceuticals Ltd. Pyridine compounds
NZ595073A (en) * 2009-04-20 2012-11-30 Hoffmann La Roche Proline derivatives as cathepsin inhibitors
US8394834B2 (en) * 2009-08-25 2013-03-12 Hoffman-La Roche Inc. Pyrrolidines as NK3 receptor antagonists
CA2850551A1 (en) 2011-09-30 2013-04-04 Endo Pharmaceuticals Inc. Pyridine derivatives

Also Published As

Publication number Publication date
MA37893A1 (fr) 2017-08-31
SG11201500900YA (en) 2015-03-30
EA025166B1 (ru) 2016-11-30
ZA201500625B (en) 2016-08-31
US9409882B2 (en) 2016-08-09
IN2015DN00962A (Direct) 2015-06-12
TW201412728A (zh) 2014-04-01
CN104583198A (zh) 2015-04-29
HK1206716A1 (en) 2016-01-15
US20150307472A1 (en) 2015-10-29
CR20150073A (es) 2015-03-13
WO2014029722A1 (en) 2014-02-27
BR112015003217A2 (pt) 2017-07-04
JP2015530997A (ja) 2015-10-29
IL237128A0 (en) 2015-03-31
EP2888244A1 (en) 2015-07-01
CL2015000354A1 (es) 2015-10-23
MX2015002026A (es) 2015-06-05
CO7200259A2 (es) 2015-02-27
AR092172A1 (es) 2015-03-25
AU2013305102A1 (en) 2015-02-12
PH12015500262A1 (en) 2015-03-30
CA2879796A1 (en) 2014-02-27
EA201590363A1 (ru) 2015-06-30
KR20150044947A (ko) 2015-04-27

Similar Documents

Publication Publication Date Title
MX2012013907A (es) Compuestos heteroarilo nitrogenados.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
ECSP11011411A (es) Derivados de prolina como inhibidores de catepsina
CR20150250A (es) Nuevos derivados de piridina
CR20150277A (es) Piridina-2-amidas utiles como agonistas cb2
ECSP13013074A (es) Nuevos derivados de piridina
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
CR20150204A (es) Nuevos derivados de piridina
CO7131360A2 (es) Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa
BR102013003576B8 (pt) Método para produzir n-ciano-s-metil-s-[1-(6-tri-flúormetil-3-piridinil)etil]sulfilimina
CO6741154A2 (es) Compuestos de triazolopiridina
CR20150440A (es) Nuevos derivados de piridina
CR20150210A (es) Nuevos derivados de pirazina como agonistas receptores de cb2
PE20142399A1 (es) Compuestos de pirazol como inhibidores de sglt1
PH12014502285A1 (en) Anti-malarial agents
BR112014016803A8 (pt) amidas macrocíclicas como inibidoras de protease
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
UY34110A (es) Procedimiento de síntesis y forma cristalina del hidrocloruro de 4-{3- [cis- hexahidrociclopenta [c ] pirrol-2(1h)-il] propoxi} benzamida así como la s composiciones farmacéuticas que la contienen
CR20150073A (es) Nuevos derivados de piridina
BR112014019180A8 (pt) Novos derivados de azetidina
TN2013000441A1 (en) 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CR20150012A (es) Compuestos de azetidina y piperidina utiles como inhibidores de pde10

Legal Events

Date Code Title Description
FD Application declared void or lapsed